

Belgian Clinical Guidance for COVID-19


- **March 2020:** Members of the Task Force:
 - Dr. Emmanuel Bottieau (ITG)
 - Dr Ralph Huits (ITG)
 - Dr Sabrina Van Ierssel (UZA)
 - Dr Nicolas Dauby (CHU-Saint-Pierre)
 - Dr Chloe Wyndham-Thomas (Sciensano)
 - Dr Roel Van Loock (AFMPS/FAGG)
- **January 2021:** Task force lead by BVIKM/SBIMC:
 - ID representatives from all Belgian University Hospitals
 - + Belgian Society of Intensive Care Medicine
 - + Belgian Society of Pneumology



Belgian Clinical Guidance for COVID-19

- Members of the New Task Force:
 - Dr. Koen Blot (Sciensano)
 - Dr. Emmanuel Bottieau (ITG)
 - Dr. Nicolas Dauby (CHU-Saint-Pierre)
 - Dr. Julien De Greef (UCL-Saint Luc)
 - Dr. Pieter Depuydt (UZ-Gent)
 - Dr. Paul De Munter (UZ Leuven)
 - Dr. Patrick Lacor (UZA)
 - Dr. Natalie Lorent (UZ Leuven)
 - Dr. Jiska Malotaux (UZ Gent)
 - Dr. Fabio Taccone (CUB-Erasme Hospital)
 - Dr. Caroline Theunissen (ITG)
 - Dr. Eva Van Braeckel (UZ Gent)
 - Dr. Sabrina Van Ierssel (UZA)
 - Dr. Roel Van Loock (AFMPS-FAGG)
 - Dr. Sandrine Milas (CHU-Charlerois)
 - Dr. Nele Steens (AFMPS-FAGG)

Belgian Clinical Guidance for COVID-19

- Treatment options for patients with suspected or confirmed cases of COVID-19
 - **Table 1:** Summary of recommendations (with strength of recommendation)
 - Guidelines for **Hospitalized** patients
- 
- Guidelines concerning **at risk patients** in **ambulatory** care

Belgian Clinical Guidance for COVID-19

- Corticosteroids
 - Remdesivir
 - Baricitinib
 - Chloroquine and hydroxychloroquine
 - Lopinavir/ritonavir
 - Favipiravir
 - Camostat mesylate
 - Azithromycin
 - Interferons
 - Immunomodulatory agents
 - Convalescent plasma
 - Monoclonal antibodies
 - Ivermectin
 - Colchicine
 - Aspirin
 - + Information concerning:
 - Anti-coagulation
 - Pregnant women
 - Children
- Drugs are divided between the task force members
 - Discussion/Update of the document: 1x/month
 - FAGG/AFMPS: helps with the physical updating of the document
(layout + references)

Belgian Clinical Guidance for COVID-19

- **Table 2:** Summary of efficacy data (*in-vitro* + *in-vivo*) of selected anti-viral drugs
- **Table 3:** Clinical Trials in Belgian

Thank you for everyone's hard work!

S

B

B

V

I


I

M

K

C

M



BVIKM SBIMC

CM-DBS
MK-VB

